Considering these cytogenetics findings in the context of the revised 2017 WHO classification system, the DLBCL component should be designated “high-grade B-cell lymphoma with MYC and BCL2 rearrangements”. This evidence concerns the gene BCL2 and B-cell non-Hodgkin lymphoma.